Key facts
- This page summarizes Teresa Marie Bitetti's Form 4 filing for TAKEDA PHARMACEUTICAL CO LTD (TAK).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Nov 2026, 17:35.
Teresa Marie Bitetti - 02 Nov 2026 Form 4 Insider Report for TAKEDA PHARMACEUTICAL CO LTD (TAK)
- Reporting relationship
- President, OBU
- Issuer ticker
- TAK
- Reported as of
- 02 Nov 2026
- Net transaction value
- -$973,662
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2026, 17:35:30 UTC
- Prior SEC filing
- 12 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kate Huleatt, by power of attorney, for Teresa Bitetti
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Teresa Marie Bitetti filed Form 4 for TAKEDA PHARMACEUTICAL CO LTD (TAK) on 04 Nov 2026.
Change
- Previous filing in this sequence was filed on 12 Aug 2026.
- Current net transaction value: -$973,662.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001977608
Primary reporting owner
Bitetti Teresa Marie
- Relationship
- President, OBU
- Address
- 40 LANDSDOWNE STREET, CAMBRIDGE
- Signature
- /s/ Kate Huleatt, by power of attorney, for Teresa Bitetti
- Signature date
- 04 Nov 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TAK
transaction
American Depositary Shares
Sale
- Transaction value
- -$973,662
- Shares
- -46,609
- Change %
- -18%
- Price
- $20.89
- Shares after
- 214,501
- Date
- 02 Nov 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Includes 9,100 ADS received upon the vesting of dividend equivalent units that were not included in the reporting person's previously filed Form 4.